BioSpace News Archive

Business

Medibio Signs Agreement With Striiv to Accelerate Commercialisation

The strategic partnership is intended to allow Striiv to integrate Medibio’s proprietary, personal mental health evaluation technology into its mobile app and assessment services, which has a user base of over 1 million subscribers.

January 22, 2018
·
3 min read
Ossur Hf: Transactions in Relation to Share Buyback Program – Jan. 22, 2018

The purpose of the share buyback program is to reduce the Company’s share capital and adjust the capital structure by distributing capital to shareholders in line with the Company’s Capital Structure and Dividend Policy.

January 22, 2018
·
2 min read
Business

BioRestorative Therapies Announces the Appointment of Adam D. Bergstein as Sr. VP, Planning and Business Development

In this capacity, Mr. Bergstein will be responsible for strategic planning, business development, capital market activities and related endeavors.

January 22, 2018
·
4 min read
Biotech Beach

Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $60.4 Million

Arrowhead Pharmaceuticals announced underwritten public offering of 11,500,000 shares of its common stock, which included shares issued upon the exercise in full by the underwriters of their option to purchase 1,500,000 additional shares.

January 22, 2018
·
2 min read
Business

Alexion Appoints Deborah Dunsire, M.D. to Its Board of Directors

Dr. Dunsire is a proven leader in the biopharmaceutical industry with three decades of experience and a successful track record of growing businesses, fostering R&D and commercial development, and creating shareholder value.

January 22, 2018
·
4 min read
Business

SillaJen and ABL Europe Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies

Under the current agreement, ABL is currently manufacturing Pexa-Vec for SillaJen’s multinational, randomized Phase 3, open-label study of Pexa-Vec in patients with advanced liver cancer.

January 22, 2018
·
4 min read
MOLOGEN Presented Lefitolimod TME Data at ASCO GI 2018

The data showed that lefitolimod can significantly improve the anti-tumor effect of checkpoint inhibitors, particularly anti-PD-1 and anti-PD-L1 antibodies, and thus prolong survival in murine tumor models.

January 22, 2018
·
5 min read
Business

KEDPLASMA USA Opens Two More Plasma Collection Centers, Re-Locates a Third; Ongoing Growth Benefits Rare Disease Patients

The new and re-located centers are part of a KEDPLASMA USA five-year plan to bring the number of plasma collection centers that it owns and operates to a total of over 30 by the year 2020.

January 22, 2018
·
5 min read
Drug Development

European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros’ OMS721 in the Treatment of IgA Nephropathy

Omeros Corporation announced today that the European Medicines Agency’s Committee for Orphan Medicinal Products issued a positive opinion on Omeros’ application for orphan drug designation of OMS721 in the treatment of primary Immunoglobulin A nephropathy (IgAN).

January 22, 2018
·
7 min read
Biotech Bay

BioTime Announces Clinical and Corporate Milestone Targets for 2018

BioTime will continue to focus on the core pillars of its stated strategy of Clinical Progress, Simplification and Unlocking Value for BioTime Shareholders.

January 22, 2018
·
7 min read